「ビスホスフォネート」

Risedronic acid
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	AU: B3; US: C (Risk not ruled out); ;
Routes of; administration	Oral
ATC code	M05BA07 (WHO);
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	0.63%
Protein binding	~24%
Metabolism	None
Biological half-life	1.5 h
Excretion	Renal and fecal
Identifiers
	IUPAC name (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid;
CAS Number	105462-24-6 ;
PubChem CID	5245;
IUPHAR/BPS	3176;
DrugBank	DB00884 ;
ChemSpider	5055 ;
UNII	KM2Z91756Z;
ChEMBL	CHEMBL923 ;
ECHA InfoCard	100.116.436
Chemical and physical data
Formula	C7H11NO7P2
Molar mass	283.112 g/mol
3D model (JSmol)	Interactive image;
	SMILES OC(Cc1cccnc1)(P(=O)(O)O)P(=O)(O)O ;
	InChI InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15) ; Key:IIDJRNMFWXDHID-UHFFFAOYSA-N ;
(what is this?) (verify)

Risedronic acid (INN) often used as its sodium salt risedronate sodium (USAN) is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. It is produced and marketed by Warner Chilcott, Sanofi-Aventis, and in Japan by Takeda under the trade names Actonel, Atelvia, and Benet. It is also available in a preparation that includes a calcium carbonate supplement, as Actonel with Calcium.

Controversies

In January 2006 P&G and its marketing partner Sanofi-Aventis filed a Lanham Act false claims lawsuit against rival drugmakers Roche and GlaxoSmithKline claiming false advertising about Boniva.^[1] The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on September 7, 2006 U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction. P&G was criticized for attempting to "preserve its market share by denigrating Boniva". Judge Crotty wrote that "Roche was clearly entitled to respond with its own data, provided that the data was truthfully and accurately presented".^[2]

In 2006, P&G faced controversy over its handling of clinical research involving risedronate (News Reports^[3] and discussion).^[4]

In common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by dental procedures inducing trauma to the bone.

References

^ "P&G Press statement". Uk.pg.com. Retrieved 2013-03-01.
^ NY fed judge finds promotions for bone drug Boniva are fair Associated Press, 7 Sept 2006^{[dead link]}
^ http://www.thejabberwock.org/wiki/index.php?title=Actonel_Case_Media_Reports
^ "Scientific Misconduct Blog". Scientific-misconduct.blogspot.com. Retrieved 2013-03-01.

External links

Actonel adverse events reported to the FDA
Risedronic acid bound to proteins in the PDB

[1] "P&G Press statement". Uk.pg.com. Retrieved 2013-03-01.

[2] NY fed judge finds promotions for bone drug Boniva are fair Associated Press, 7 Sept 2006^{[dead link]}

[3] ttp://www.thejabberwock.org/wiki/index.php?title=Actonel_Case_Media_Reports

[4] "Scientific Misconduct Blog". Scientific-misconduct.blogspot.com. Retrieved 2013-03-01.

v t e Drugs for treatment of bone diseases (M05)
Bisphosphonates	Nitrogenous (Alendronic acid ibandronic acid incadronic acid pamidronic acid risedronic acid zoledronic acid) Non-nitrogenous (Etidronic acid clodronic acid tiludronic acid)
Bone morphogenetic proteins	Dibotermin alfa Eptotermin alfa
Other	Resorption inhibitor (Ipriflavone) Aluminium chlorohydrate Dual action bone agent (Strontium ranelate) RANKL inhibitor (Denosumab) Cathepsin K inhibitor (Odanacatib) Calcium Vitamin D

リンク元	「ビスホスフォネート」「リセドロン酸」「risedronic acid」
拡張検索	「sodium risedronate hydrate」

	タイトル	表示
1	user/password	20
2	Jardine, A., Neville, P. J., Dent, C., Webster, C., & Lindsay, M. D. (2014). Ross River virus risk associated with dispersal of Aedes (Ochlerotatus) camptorhynchus (Thomson) from breeding habitat into surrounding residential areas: muddy lakes, Western Australia. American Journal of Tropical Medicineand Hygiene, 91(1), 101-108. doi:10.4269/ajtmh.13-0399	16
3	多毛日本	12
4	cefpodoxime proxetil BCS	8
5	user/register	8
6	1,320,568,24 HTTP/1.1	8
7	盲斑	7
8	ラクテック	6
9	1,1024,768,24 HTTP/1.1	6
10	ルリッシュ症候群	5
11	viraldeath解剖	5
12	サイズの原理筋電図	5
13	?testosterone decanoate? Britain	4
14	?mesterolon? Europe	4
15	メトロイリーゼ	4
16	?mesterolon? Britain	4
17	ヒドロキシウレア	4
18	ハルトマン	4
19	vitブラウザの1時間2.3時間を見る方法	4
20	?mesterolon? Germany	4

	タイトル	表示
1	アンドロゲン過剰症	4
2	気管軟骨	3
3	オマリズマブ　血清IgE値	3
4	交差試験主試験	3
5	スルホン酸　スルフィン酸　スルフェン酸	2
6	胎児下降度　英語	2
7	ジャクソンテストの表示	2
8	体液量ホルモン	2
9	気管憩室	2
10	マンノース6-リン酸生命現象	2
11	クッシング徴候	2
12	児頭下降度	2
13	皮膚割線	2
14	ラセナゾリン	2
15	眼白子症	2
16	垂直距骨	2
17	インドメタシンファルネシル　構造	2
18	1,320,568,24 HTTP/1.1	2
19	トルサデポアン波形	2
20	user/register	2

出典: meddic

Wikipedia preview

wiki en

Contents

Controversies

See also

References

External links

UpToDate Contents

英文文献

和文文献

関連リンク

関連画像

★リンクテーブル★

「ビスホスフォネート」

「リセドロン酸」

添付文書

「risedronic acid」

「sodium risedronate hydrate」

★コメント★

表示

個人用ツール

医学用語集めでぃっく

最初に

臨床医学

基礎医学

リンク

連絡

週間・日々の人気記事

最近7日間の人気記事

昨日の人気記事

医学用語集meddic.jp

Clinical data

AHFS/Drugs.com	International Drug Names
Pregnancy category	AU: B3 US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	M05BA07 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	0.63%
Protein binding	~24%
Metabolism	None
Biological half-life	1.5 h
Excretion	Renal and fecal
Identifiers
IUPAC name (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid
CAS Number	105462-24-6^Y
PubChem CID	5245
IUPHAR/BPS	3176
DrugBank	DB00884^N
ChemSpider	5055^N
UNII	KM2Z91756Z
ChEMBL	CHEMBL923^N
ECHA InfoCard	100.116.436
Chemical and physical data
Formula	C₇H₁₁NO₇P₂
Molar mass	283.112 g/mol
3D model (JSmol)	Interactive image
SMILES OC(Cc1cccnc1)(P(=O)(O)O)P(=O)(O)O
InChI InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)^N Key:IIDJRNMFWXDHID-UHFFFAOYSA-N^N
^NY (what is this?) (verify)

ニックネーム：
コメント：